OINDPnews


H&T Presspart Low GWP Banner

Business

Optinose partners with Kaleo for promotion of Xhance intranasal fluticasone

Optinose announced that it has signed an agreement with Kaleo for co-promotion of Optinose's Xhance fluticasone propionate nasal spray for the treatment of nasal polyps. Xhance was approved by the FDA for that indication in September 2017. The agreement calls for Kaleo to promote the nasal spray to a group of almost 6,000 healthcare providers in the US.   Optinose … [Read more...] about Optinose partners with Kaleo for promotion of Xhance intranasal fluticasone

Altimmune partners with DynPort Vaccine on intranasal COVID-19 vaccine

Altimmune said that it has signed an agreement with DynPort Vaccine Company regarding Altimmune's AdCovid intranasal vaccine candidate for COVID-19. The company announced in March 2020 that it had partnered with the University of Alabama Birmingham to develop AdCOVID. According to Altimmune, "The partnership with DVC significantly expands Altimmune’s capabilities … [Read more...] about Altimmune partners with DynPort Vaccine on intranasal COVID-19 vaccine

BNC Korea acquires rights to Iconovo’s generic versions of Ultibro and Seebri for Asia, CIS countries

Iconovo announced that BNC Korea has acquired rights to manufacture and market generic versions of Ultibro indacaterol/glycopyrronium and Seebri glycopyrronium DPIs based on Iconovo formulations and the company's ICOcap device. The deal covers a territory that includes Korea, Japan, China, Taiwan, Turkey, and Russia, as well as additional CIS and southeast Asian … [Read more...] about BNC Korea acquires rights to Iconovo’s generic versions of Ultibro and Seebri for Asia, CIS countries

Meissa Vaccines provides update on intranasal vaccines for COVID-19, RSV

Meissa Vaccines has provided updates on two intranasal live attenuated vaccines (LAVs) based on its "codon deoptimized RSV vaccine platform with the goal of creating safe, potent, stable, and cost-effective intranasal vaccines." The company said that it held a pre-IND meeting with the FDA regarding its MV-014-210 for prevention of SARS-CoV-2 and that it intends to … [Read more...] about Meissa Vaccines provides update on intranasal vaccines for COVID-19, RSV

Tiziana announces progress on development of TZLS-501 inhaled anti-IL-6R mAb for COVID-19

Tiziana Life Sciences has announced a new agreement with STC Biologics for manufacturing of its TZLS-501 inhaled anti-IL-6 receptor monoclonal antibody. The company said that it is also working with Sciarra Laboratories to develop a nebulizer for delivery of TZLS-501 for the treatment of COVID-19. In addition, Tiziana said that it had submitted a patent application … [Read more...] about Tiziana announces progress on development of TZLS-501 inhaled anti-IL-6R mAb for COVID-19

EverInsight Therapeutics gets Asian rights to VistaGen’s PH94B nasal spray

VistaGen Therapeutics has announced that it signed a deal giving EverInsight Therapeutics development and commercialization rights to Vistagen's PH94B aloradine nasal spray for anxiety disorders in China, South Korea, and a number of other Asian countries. EverInsight, funded by the CBC Group, is paying $5 million up front, plus a potential $172 million in milestone … [Read more...] about EverInsight Therapeutics gets Asian rights to VistaGen’s PH94B nasal spray

Renovion raises $8.1 million for development of inhaled mucolytic

North Carolina-based Renovion said that it has raised $8.1 million in a Series A financing round for development of its ARINA-1 nebulized glutathione/bicarbonate/ascorbic acid formulation for the treatment of chronic lung diseases. ARINA-1, which is delivered via the PARI eFlow nebulizer system, has been granted orphan drug designation by the FDA for the treatment of … [Read more...] about Renovion raises $8.1 million for development of inhaled mucolytic